Publications by authors named "A Kirillova"
Background: Pulmonary arterial hypertension (PAH) is a deadly disease without effective non-invasive diagnostic and prognostic testing. It remains unclear whether vasodilators reverse inflammatory activation, a part of PAH pathogenesis. Single-cell profiling of inflammatory cells in blood could clarify these PAH mechanisms.
View Article and Find Full Text PDFPurpose: To determine how clinical, demographic, and laboratory characteristics influence ovarian tissue oocyte quality.
Methods: Immature cumulus-oocyte complexes were isolated from removed ovaries and cultured for 48-52 h in either monophasic standard or biphasic CAPA media for fertility preservation. A total of 355 MII oocytes from 53 patients were described for intracytoplasmic and extracytoplasmic anomalies.
Bioprinting describes the printing of biomaterials and cell-laden or cell-free hydrogels with various combinations of embedded bioactive molecules. It encompasses the precise patterning of biomaterials and cells to create scaffolds for different biomedical needs. There are many requirements that bioprinting scaffolds face, and it is ultimately the interplay between the scaffold's structure, properties, processing, and performance that will lead to its successful translation.
View Article and Find Full Text PDFBackground: Left heart disease is the most common cause of pulmonary hypertension (PH) and is frequently accompanied by increases in pulmonary vascular resistance. However, the distinction between phenotypes of PH due to left heart disease with a normal or elevated pulmonary vascular resistance-isolated postcapillary PH (IpcPH) and combined pre- and postcapillary PH (CpcPH), respectively-has been incompletely defined using unbiased methods.
Methods And Results: Patients with extremes of IpcPH versus CpcPH were identified from a single-center record of those who underwent right heart catheterization.
Article Synopsis
- Hypercontractility and arrhythmia are significant issues in hypertrophic cardiomyopathy (HCM), and while beta-blockers are the standard treatment, they can lead to unwanted side effects like fatigue and lowered cardiac output.
- Researchers screened 21 different beta-blockers and found that carvedilol, which is not commonly used for HCM, effectively reduces heart muscle contractility and arrhythmia through inhibition of the ryanodine receptor type 2 (RyR2) without dropping heart rate.
- The study suggests that carvedilol’s unique properties, particularly its R-enantiomer, may offer a promising alternative treatment for HCM patients, combining antiarrhythmic effects and reduced contractility without compromising overall heart performance.